Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04VPA
|
||||
Former ID |
DAP000510
|
||||
Drug Name |
Moricizine
|
||||
Synonyms |
Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiarrhythmic Agents
|
||||
Company |
Shire Development Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H25N3O4S
|
||||
InChI |
InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)
|
||||
InChIKey |
FUBVWMNBEHXPSU-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 31883-05-3
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9945, 4026447, 7388142, 7980016, 8173724, 11112721, 11137751, 11467079, 11468199, 11486667, 11500554, 14782938, 25680943, 34676267, 46509072, 47206804, 47377252, 47897104, 47971880, 48271403, 48271404, 48346667, 48416294, 49699387, 49900350, 50086819, 50105209, 50236557, 56459387, 57311701, 58007385, 61030619, 85788904, 92289659, 93166657, 103293612, 104222092, 104319116, 106034887, 117439362, 117439364, 117579671, 124513927, 124882570, 124882571, 124882572, 125163413, 125824582, 127899847, 134337803
|
||||
SuperDrug ATC ID |
C01BG01
|
||||
SuperDrug CAS ID |
cas=031883053
|
||||
Target and Pathway | |||||
Target(s) | Sodium channel protein type 5 subunit alpha | Target Info | Blocker | [537980] | |
KEGG Pathway | Adrenergic signaling in cardiomyocytes | ||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Interaction between L1 and Ankyrins | ||||
References | |||||
Ref 538532 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019753. | ||||
Ref 542261 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7244). | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.